SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : XOMA. Bull or Bear? -- Ignore unavailable to you. Want to Upgrade?


To: aknahow who wrote (8423)1/22/1999 3:14:00 PM
From: Cacaito  Read Replies (1) | Respond to of 17367
 
ABTI discontinues PIII trial of Btafectin in Surgery patients.

Check prnewswire jan 22/1999.

This is the last gasp of ABTI on Betafectin and probably the company
itself.



To: aknahow who wrote (8423)1/24/1999 9:15:00 PM
From: Robert S.  Read Replies (1) | Respond to of 17367
 
George...

So in any event regardless of which theory is correct, with each day that passes the data becomes more robust.

At what point, if ever, does this ongoing good news become an albatross?